Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX3 Bevacizumab in Refractory Metastatic Colorectal Cancer
NCT03795311Phase 2Active, not recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Nov 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Centre Georges-François Leclerc. Primary endpoints: Number of Participants with Acute toxicities as a Measure of treatment specific Safety and Tolerability up to 6 months and Objective Response Rate according to RECIST criteria. Started Nov 2018; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03795311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795311.